Related Experiment Video

Updated: Apr 17, 2026

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus
07:10

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

975

2013 viral clearance symposia - session 5. Conference summary: key discussion and outcomes, pending questions, and

Johannes Blümel1, David Roush2

  • 1Paul-Ehrlich-Institut; and david_roush@merck.com Johannes.Bluemel@pei.de.

PDA Journal of Pharmaceutical Science and Technology
|February 19, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.3K

Related Concept Videos

Drug Clearance: Overview01:06

Drug Clearance: Overview

Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
603